<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02061332</url>
  </required_header>
  <id_info>
    <org_study_id>807010</org_study_id>
    <secondary_id>15107</secondary_id>
    <nct_id>NCT02061332</nct_id>
    <nct_alias>NCT00923143</nct_alias>
  </id_info>
  <brief_title>DC Vaccine for Patients With Ductal Carcinoma In Situ</brief_title>
  <acronym>DCIS6</acronym>
  <official_title>A Randomized Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women who are diagnosed with Her-2/neu over-expressing DCIS will receive DC1 vaccines by
      intranodal, intralesional, or both routes of administration. The primary objective will be
      safety and administration with secondary objectives of immune activation and clinical
      response.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The treatment of patients with DCIS can be individualized and tailored to the type of DCIS
      and the relative risk of the lesion. HER-2/neu over-expressing DCIS represents a group of
      patients with significant risk for development of invasive breast cancer. In this proposal we
      will continue to evaluate the development of type I polarized DC for the treatment of DCIS by
      evaluating whether further improvements in therapeutic response can be achieved by
      intratumoral administration of HER-2/neu pulsed DC1 compared with our current intranodal
      administration. Women who are diagnosed with Her-2/neu over-expressing DCIS with no invasive
      carcinoma will be eligible for this study. Patients will receive DC1 vaccines by intranodal,
      intralesional, or both routes of administration. The primary objective will be safety and
      administration with secondary objectives of immune activation and clinical response. We will
      also develop a novel assay to monitor ongoing immunity to HER-2/neu, and lastly will begin to
      develop these vaccines for patients with invasive breast cancer as well. Fifty-four subjects
      will be randomized to one of three treatment arms: intranodal injection, intralesional
      injection, or intranodal and intralesional injection of the vaccine. Upon entering this
      study, the subjects' blood will be drawn in a way that collects only the white blood cells.
      Subjects then receive six vaccines over a six week period. They will then undergo the
      standard surgical procedure to remove any remaining DCIS in the breast.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>up to 60 minutes post vaccine</time_frame>
    <description>Blood pressure will be obtained just prior to the vaccination then, every 15 minutes for the first hour after the dose is given.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Temperature</measure>
    <time_frame>up to 60 minutes post vaccine</time_frame>
    <description>Temperature will be obtained just prior to the vaccination then, every 15 minutes for the first hour after the dose is given.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse</measure>
    <time_frame>up to 60 minutes post vaccine</time_frame>
    <description>Pulse will be obtained just prior to the vaccination then, every 15 minutes for the first hour after the dose is given.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>Subjects will undergo leukapheresis after completion of 6 vaccines and 3 boost vaccines for the purpose of obtaining lymphocytes and monocytes for in vitro immunologic testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mammogram</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>All subjects will have a post-vaccine bilateral mammogram to evaluate response to vaccination. Mammograms will be performed within two weeks after the 6th vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI</measure>
    <time_frame>6-8 weeks</time_frame>
    <description>All subjects will have a post-vaccine bilateral breast MRI to evaluate response to vaccination. MRIs will be performed within two weeks after the 6th vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Breast Cancer</condition>
  <condition>DCIS</condition>
  <arm_group>
    <arm_group_label>Intranodal Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An ultrasound device (probe) will be placed over the area of the groin or armpit. The vaccine needle will then be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes per visit. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into 1-2 different groin lymph nodes or axillary nodes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intralesional Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The HER-2 pulsed dendritic cell vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells and will be injected into the quadrant of the breast affected with DCIS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranodal + Intralesional Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>You will be given a HER-2 pulsed dendritic cell vaccine in two different groin lymph nodes or axillary nodes and the quadrant of the breast affected with DCIS. An ultrasound device (probe) will be placed over the groin or armpit. The vaccine needle will be placed under the probe, and guided by the ultrasound machine to the groin lymph nodes or axillary nodes. The intralesional vaccine will be directly injected into the quadrant of the breast affected with DCIS. The location will be determined by referring to the patient's mammogram. Each dose will consist of 1.0-2.0 x 107 cells. Approximately half of the dose will be injected into 1-2 different groin lymph nodes or axillary nodes. The remaining half will be injected into the quadrant of the breast affected with DCIS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HER-2 Pulsed Dendritic cell Vaccine</intervention_name>
    <description>6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.</description>
    <arm_group_label>Intranodal Vaccine</arm_group_label>
    <arm_group_label>Intralesional Vaccine</arm_group_label>
    <arm_group_label>Intranodal + Intralesional Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years.

          -  Subjects with biopsy-proven DCIS, DCIS with microinvasion, DCIS with invasive disease
             under 5 mm, or Paget's Disease of the nipple (DCIS of the nipple) who have not yet
             received definitive treatment.

          -  HER-2/neu positive tumor as determined by &gt;5% of tumor population expressing this
             marker by immunohistochemical staining 2+ using anti-HER-2/neu verified by Dr. Paul
             Zhang in the Department of Pathology.

          -  Women of childbearing age with a negative pregnancy test documented prior to
             enrollment.

          -  Subjects with ECOG Performance Status Score of 0 or 1 (Appendix D).

          -  Subjects willing to use birth control if necessary

          -  Subjects who have voluntarily signed a written Informed Consent in accordance with
             institutional policies after its contents have been fully explained to them.

        Exclusion Criteria:

          -  Pregnant or lactating females (pregnancy testing to be performed within 7 days prior
             to administration of first dose of vaccine).

          -  Subjects who have had a complete excisional biopsy of their tumor.

          -  Subjects with suspicion of invasive disease &gt; 5mm by MRI performed within 2 months of
             study recruitment.

          -  Screen and exclude subjects with positive HIV or hepatitis C at baseline.

          -  Subjects with coagulopathies, including thrombocytopenia with platelet count &lt;75,000,
             INR &gt; 1.5 and partial thromboplastin time &gt; 50 sec

          -  Subjects with major cardiac illness MUGA &lt; 50% EF.

          -  Subjects with pre-existing medical illnesses or medications which might interfere with
             the study.

          -  Subjects with laboratory tests reflecting Â¬&gt; grade 1 toxicity by NCI CTC version 3.0
             including CBC, liver function tests, urinalysis, EKG if cannot be corrected on repeat
             test in 7 days.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian J Czerniecki, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res. 2007 Jul 15;67(14):6531-4. Review.</citation>
    <PMID>17638860</PMID>
  </reference>
  <reference>
    <citation>Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weinstein S, Orel SG, Vonderheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res. 2007 Feb 15;67(4):1842-52. Epub 2007 Feb 9.</citation>
    <PMID>17293384</PMID>
  </reference>
  <reference>
    <citation>Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Czerniecki BJ. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother. 2012 Jan;35(1):54-65. doi: 10.1097/CJI.0b013e318235f512.</citation>
    <PMID>22130160</PMID>
  </reference>
  <reference>
    <citation>Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, Zhang P, Koski G, Czerniecki BJ. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer. 2012 Sep 1;118(17):4354-62. doi: 10.1002/cncr.26734. Epub 2012 Jan 17.</citation>
    <PMID>22252842</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2014</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>DCIS</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Dendritic Cell</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

